<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Clinical Medicine2077-0383MDPI doi: 10.3390/jcm9041138jcm-09-01138 : Editorial Global Spread of Coronavirus" exact="Disease" post="2019 and Malaria: An Epidemiological Paradox in the Early"/>
 <result pre="work, we discovered and analyzed the epidemiological paradox between coronavirus" exact="disease" post="2019 (COVID-19) and malaria in the initial phase of"/>
 <result pre="analyzed the epidemiological paradox between coronavirus disease 2019 (COVID-19) and" exact="malaria" post="in the initial phase of the ongoing pandemic. From"/>
 <result pre="From the analysis of distribution data, the endemic presence of" exact="malaria" post="seems to protect some populations from COVID-19 outbreak, particularly"/>
 <result pre="countries. In this sense, molecular and genetic variations associated with" exact="malaria" post="(e.g., in ACE2) might play a protective role against"/>
 <result pre="toward the study of some currently available medications. COVID-19 coronavirus" exact="disease" post="malaria antimalarials ACE-2 receptor epidemiological paradox 1. Introduction The"/>
 <result pre="the study of some currently available medications. COVID-19 coronavirus disease" exact="malaria" post="antimalarials ACE-2 receptor epidemiological paradox 1. Introduction The recent"/>
 <result pre="receptor epidemiological paradox 1. Introduction The recent spread of coronavirus" exact="disease" post="2019 (COVID-19) constitutes an important and unsolved public health"/>
 <result pre="pandemic and, in particular, regarding the involvement of the poorest" exact="African" post="countries. In the latter, the scarce economic resources, the"/>
 <result pre="health system, and the endemic presence of diseases associated with" exact="immunodeficiency" post="(i.e., AIDS) may make the containment of the outbreak"/>
 <result pre="some types of betacoronaviruses (Beta-CoVs), such as the Middle East" exact="respiratory" post="syndrome-related coronavirus (MERS-CoV), have proven to be resistant to"/>
 <result pre="3Â°8â€²N 101Â°41â€²E). The novel Beta-CoV responsible for COVID-19, named â€œsevere" exact="acute" post="respiratory syndrome coronavirus 2â€� (SARS-CoV-2), may have some characteristics"/>
 <result pre="101Â°41â€²E). The novel Beta-CoV responsible for COVID-19, named â€œsevere acute" exact="respiratory" post="syndrome coronavirus 2â€� (SARS-CoV-2), may have some characteristics in"/>
 <result pre="The novel Beta-CoV responsible for COVID-19, named â€œsevere acute respiratory" exact="syndrome" post="coronavirus 2â€� (SARS-CoV-2), may have some characteristics in common"/>
 <result pre="historical data relating to SARS-CoVs and MERS-CoV epidemics reveal a" exact="limited" post="or no dissemination of these disorders in African countries,"/>
 <result pre="reveal a limited or no dissemination of these disorders in" exact="African" post="countries, despite the limitations of the health system and"/>
 <result pre="Wuhan) and in some countries of South America, a relatively" exact="limited" post="number of cases of COVID-19 have occurred during the"/>
 <result pre="report has documented an increase in the death rate for" exact="pneumonia" post="of unknown causes. Accordingly, alternative hypotheses can be derived"/>
 <result pre="maps of Beta-CoVs diseases (i.e., MERS, SARS, and COVID-19) and" exact="malaria" post="through which it is possible to reveal an inverse"/>
 <result pre="(CET), i.e., after approximately three months of pandemic, merely 247" exact="total" post="cases of COVID-19 (with six deaths) have been detected"/>
 <result pre="COVID-19 (with six deaths) have been detected in the six" exact="African" post="countries with the highest number of malaria cases, which"/>
 <result pre="in the six African countries with the highest number of" exact="malaria" post="cases, which are defined by the World Malaria Report"/>
 <result pre="number of malaria cases, which are defined by the World" exact="Malaria" post="Report 2019 (Figure 1D, WHO data source). Specifically, in"/>
 <result pre="(~400 million of people) associated with a variable percentage of" exact="malaria" post="patients out of global cases: Nigeria (25%), the Democratic"/>
 <result pre="COVID-19 increases to 25 and 2,156, respectively, out of a" exact="total" post="of ~2 billion people (Figure 1D, WHO data source)."/>
 <result pre="WHO data source). 3. Hypotheses and Discussion The assumption that" exact="malaria" post="has a protective effect against recent Beta-CoVs epidemics seems"/>
 <result pre="premises. Firstly, the presence of an evolutionary adaptation related to" exact="malaria" post="(in the endemic areas or in those where it"/>
 <result pre="drugs are currently used in Western countries, mainly for some" exact="autoimmune" post="disorders, and monitored over the years, particularly to verify"/>
 <result pre="disorders, and monitored over the years, particularly to verify their" exact="ocular" post="toxicity (â€˜chloroquine retinopathyâ€™). Of note, literature data on the"/>
 <result pre="mg per day for ten days in the treatment of" exact="symptomatic" post="SARS-CoV-2 pneumonia [15]. The mechanism of action of these"/>
 <result pre="day for ten days in the treatment of symptomatic SARS-CoV-2" exact="pneumonia" post="[15]. The mechanism of action of these antimalarial drugs"/>
 <result pre="used in several countries in the treatment and prevention of" exact="malaria" post="despite drug resistance or government recommendations (also through its"/>
 <result pre="note that travelers planning a trip to some countries where" exact="malaria" post="is endemic must take these drugs for prophylaxis, thus"/>
 <result pre="take these drugs for prophylaxis, thus reducing the possibility of" exact="viral" post="transmission. From all these considerations, it is possible to"/>
 <result pre="derivatives, and other antimalarials may represent an unintentional chemoprophylaxis in" exact="African" post="countries against Beta-CoVs epidemics, which potentially slows down the"/>
 <result pre="Therefore, the involuntary achievement of an indirect protection from SARS-CoV-2" exact="infection" post="(similar to &quot;herd immunity&quot;) for individuals who are not"/>
 <result pre="to &quot;herd immunity&quot;) for individuals who are not immune, in" exact="malaria" post="countries, is likely to occur for different reasons. This"/>
 <result pre="of cases. Starting from the analysis of epidemiological data on" exact="malaria" post="and on the effectiveness of antimalarials in the treatment"/>
 <result pre="effect of the administration of chloroquine derivatives in areas where" exact="malaria" post="is endemic seems to preserve these geographic areas (i.e.,"/>
 <result pre="famous example of successful repurposed drug is Viagra (Pfizer) for" exact="erectile dysfunction" post="(angina represents its original indication). Testing these assumptions could"/>
 <result pre="doses, and contraindications, in some subcategories of the population (i.e.," exact="G6PD deficiency," post="pregnancy, etc.), have long been known. 4. Conclusions In"/>
 <result pre="Nioi, Matteo and Napoli, Pietro Emanuele, Global Spread of Coronavirus" exact="Disease" post="2019 and Malaria: An Epidemiological Paradox. (March 10, 2020)."/>
 <result pre="health emergency of international concernEurosurveillance20202510.2807/1560-7917.ES.2020.25.5.200131e 2.GilbertM.PullanoG.PinottiF.ValdanoE.PolettoC.BoÃ«lleP.Y.Dâ€™OrtenzioE.YazdanpanahY.EholieS.P.AltmannM.et al.Preparedness and vulnerability of" exact="African" post="countries against importations of COVID-19: A modelling studyLancet202039587187710.1016/S0140-6736(20)30411-632087820 3.AltamimiA.AhmedA.E.Climate"/>
 <result pre="A modelling studyLancet202039587187710.1016/S0140-6736(20)30411-632087820 3.AltamimiA.AhmedA.E.Climate factors and incidence of Middle East" exact="respiratory" post="syndrome coronavirusJ. Infect. Public Health201910.1016/j.jiph.2019.11.01131813836 4.GuarnerJ.Three emerging Coronaviruses in"/>
 <result pre="modelling studyLancet202039587187710.1016/S0140-6736(20)30411-632087820 3.AltamimiA.AhmedA.E.Climate factors and incidence of Middle East respiratory" exact="syndrome" post="coronavirusJ. Infect. Public Health201910.1016/j.jiph.2019.11.01131813836 4.GuarnerJ.Three emerging Coronaviruses in two"/>
 <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerg. Microbes Infect.2020922123610.1080/22221751.2020.171990231987001 6.WHO Coronavirus Disease 2019"/>
 <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg. Microbes Infect.2020922123610.1080/22221751.2020.171990231987001 6.WHO Coronavirus Disease 2019"/>
 <result pre="with atypical pneumonia after visiting WuhanEmerg. Microbes Infect.2020922123610.1080/22221751.2020.171990231987001 6.WHO Coronavirus" exact="Disease" post="2019 (COVID-19) Situation Reportâ€&quot;702020Available online: https://reliefweb.int/sites/reliefweb.int/files/resources/20200328-sitrep-68-covid-19.pdf(accessed on 31 March"/>
 <result pre="online: https://www.who.int/emergencies/mers-cov/maps-september-2017/en/(accessed on 31 March 2020) 9.World Health Organization: World" exact="Malaria" post="Report 20192019Available online: https://www.who.int/publications-detail/world-malaria-report-2019(accessed on 31 March 2020) 10.DrissA.HibbertJ.M.WilsonN.O.IqbalS.A.AdamkiewiczT.V.StilesJ.K.Genetic"/>
 <result pre="online: https://www.who.int/publications-detail/world-malaria-report-2019(accessed on 31 March 2020) 10.DrissA.HibbertJ.M.WilsonN.O.IqbalS.A.AdamkiewiczT.V.StilesJ.K.Genetic polymorphisms linked to" exact="susceptibility to" post="malariaLancet Infect. Dis.2020372272710.1186/1475-2875-10-27121929748 11.Gallego-DelgadoJ.RodriguezA.Malaria and hypertension. Another co-evolutionary adaptation?Front."/>
 <result pre="hypertension. Another co-evolutionary adaptation?Front. Cell. Infect. Microbiol.2014412110.3389/fcimb.2014.0012125232536 12.SilvaL.S.Silva-FilhoJ.L.Caruso-NevesC.PinheiroA.A.S.New concepts in" exact="malaria" post="pathogenesis: The role of the renin-angiotensin systemFront. Cell. Infect."/>
 <result pre="the renin-angiotensin systemFront. Cell. Infect. Microbiol.2016510310.3389/fcimb.2015.0010326779452 13.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine on" exact="viral" post="infections: An old drug against todayâ€™s diseasesLancet Infect. Dis.2003372272710.1016/S1473-3099(03)00806-514592603"/>
 <result pre="Infect. Dis.2003372272710.1016/S1473-3099(03)00806-514592603 14.VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NichoS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 15.DyallJ.GrossR.KindrachukJ.JohnsonR.F.OlingerG.G.HensleyL.E.FriemanM.B.JahrlingP.B.Middle East respiratory syndrome and severe"/>
 <result pre="inhibitor of SARS coronavirus infection and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 15.DyallJ.GrossR.KindrachukJ.JohnsonR.F.OlingerG.G.HensleyL.E.FriemanM.B.JahrlingP.B.Middle East" exact="respiratory" post="syndrome and severe acute respiratory syndrome: Current therapeutic options"/>
 <result pre="of SARS coronavirus infection and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 15.DyallJ.GrossR.KindrachukJ.JohnsonR.F.OlingerG.G.HensleyL.E.FriemanM.B.JahrlingP.B.Middle East respiratory" exact="syndrome" post="and severe acute respiratory syndrome: Current therapeutic options and"/>
 <result pre="infection and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 15.DyallJ.GrossR.KindrachukJ.JohnsonR.F.OlingerG.G.HensleyL.E.FriemanM.B.JahrlingP.B.Middle East respiratory syndrome and severe" exact="acute" post="respiratory syndrome: Current therapeutic options and potential targets for"/>
 <result pre="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 15.DyallJ.GrossR.KindrachukJ.JohnsonR.F.OlingerG.G.HensleyL.E.FriemanM.B.JahrlingP.B.Middle East respiratory syndrome and severe acute" exact="respiratory" post="syndrome: Current therapeutic options and potential targets for novel"/>
 <result pre="of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.00532173110 17.OcanM.AkenaD.NsobyaS.KamyaM.R.SenonoR.KinengyereA.A.ObukuE.A.Persistence of chloroquine resistance alleles in" exact="malaria" post="endemic countries: A systematic review of burden and risk"/>
 <result pre="analogs as a promising strategy for the treatment of emerging" exact="viral" post="diseasesPharmacol. Res. Perspect.20175e0029310.1002/prp2.29328596841 19.Dâ€™AlessandroS.ScaccabarozziD.SignoriniL.PeregoF.IlboudoD.P.FerranteP.DelbueS.The Use of Antimalarial Drugs against"/>
 <result pre="viral diseasesPharmacol. Res. Perspect.20175e0029310.1002/prp2.29328596841 19.Dâ€™AlessandroS.ScaccabarozziD.SignoriniL.PeregoF.IlboudoD.P.FerranteP.DelbueS.The Use of Antimalarial Drugs against" exact="Viral" post="InfectionMicroorganisms202088510.3390/microorganisms801008531936284 20.HarrisonC.Coronavirus puts drug repurposing on the fast trackNat."/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov.2020610.1038/s41421-020-0156-032194981 Figure 1 Distribution maps of betacoronaviruses"/>
 <result pre="Panel A shows the map representing the spread of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV) in the terminal phase"/>
 <result pre="A shows the map representing the spread of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV) in the terminal phase of"/>
 <result pre="shows the map representing the spread of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV) in the terminal phase of epidemic"/>
 <result pre="panel B represents the confirmed global cases of Middle East" exact="respiratory" post="syndrome-related coronavirus (MERS-CoV) 2012-2017 as of 1 September 2017"/>
 <result pre="C represents the map of countries with indigenous cases of" exact="malaria" post="in 2000 and their status by 2017 (WHO data"/>
 <result pre="source) [9].In panel D is shown the distribution of coronavirus" exact="disease" post="2019 (COVID-19) cases as of 25 March 2020 (WHO"/>
</results>
